{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:56:28Z","timestamp":1787954188978,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle, sarcopenia, has been associated with poor performance status and worse oncological outcomes. We studied patients with metastatic breast cancer receiving alpelisib, to determine if sarcopenia and additional body composition measures accounting for muscle and adiposity are associated with toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational analysis was conducted, including 38 women with metastatic breast cancer and a PIK3CA mutation, treated with alpelisib as advanced line of therapy. Sarcopenia was determined by measuring skeletal muscle cross-sectional area at the third lumbar vertebra using computerized tomography. Various body composition metrics were assessed along with drug toxicity, dose reductions, treatment discontinuation, hospitalizations, time to treatment failure and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sarcopenia was observed in half of the patients (n\u2009=\u200919, 50%), spanning normal weight, overweight, and obese individuals. Among the body composition measures, lower skeletal muscle density (SMD) was associated with an increased risk of treatment-related hyperglycaemia (P\u2009=\u20090.03). Additionally, lower visceral adipose tissue (VAT) was associated with alpelisib-induced rash (P\u2009=\u20090.04) and hospitalizations (P\u2009=\u20090.04). Notably, alpelisib treatment discontinuation was not impacted by alpelisib toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Body composition measures, specifically SMD and VAT may provide an opportunity to identify patients at higher risk for severe alpelisib related hyperglycemia, and cutaneous toxicity. These findings suggest the potential use of body composition assessment to caution toxicity risk, allowing for personalized therapeutic observation and intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-024-07315-9","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T12:01:15Z","timestamp":1712491275000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Body composition measures as a determinant of Alpelisib related toxicity"],"prefix":"10.1007","volume":"206","author":[{"given":"Eliya","family":"Shachar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uriel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Kessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit Strulov","family":"Shachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,7]]},"reference":[{"issue":"6","key":"7315_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD et al (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"7315_CR2","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"RT Chlebowski","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women\u2019s health initiative randomized trial. JAMA 289(24):3243. https:\/\/doi.org\/10.1001\/jama.289.24.3243","journal-title":"JAMA"},{"issue":"10","key":"7315_CR3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/1055-9965.EPI-18-0098","volume":"27","author":"RM Pfeiffer","year":"2018","unstructured":"Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH (2018) Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 27(10):1214\u20131222. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0098","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"7315_CR4","unstructured":"Cancer of the Breast (Female) \u2013 Cancer Stat Facts. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html.Accessed 27 Feb 2024"},{"issue":"5","key":"7315_CR5","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J Natl Cancer Inst 106(5):dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"7315_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4475","volume":"5","author":"D Juric","year":"2019","unstructured":"Juric D, Janku F, Rod\u00f3n J et al (2019) Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 5(2):e184475. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4475","journal-title":"JAMA Oncol"},{"issue":"1","key":"7315_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ijms14010108","volume":"14","author":"R Garc\u00eda-Becerra","year":"2012","unstructured":"Garc\u00eda-Becerra R, Santos N, D\u00edaz L, Camacho J (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14(1):108\u2013145. https:\/\/doi.org\/10.3390\/ijms14010108","journal-title":"Int J Mol Sci"},{"issue":"7418","key":"7315_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton RS, McLellan MD et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"5","key":"7315_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch C, Huang A, Chatenay-Rivauday C et al (2014) Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 13(5):1117\u20131129. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0865","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"7315_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"2","key":"7315_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-022-06741-x","volume":"196","author":"GFP Aleixo","year":"2022","unstructured":"Aleixo GFP, Valente SA, Wei W, Moore HCF (2022) Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer. Breast Cancer Res Treat 196(2):323\u2013328. https:\/\/doi.org\/10.1007\/s10549-022-06741-x","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"7315_CR12","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-16-2266","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M et al (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23(14):3537\u20133543. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2266","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7315_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"7315_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE)"},{"key":"7315_CR15","unstructured":"NHLBI Obesity Education Initiative Expert Panel on the Identification E (1998) Body Mass Index \u2013 how to measure obesity. National Heart, Lung, and Blood Institute. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1997\/.Accessed 14 Apr 2023"},{"issue":"2","key":"7315_CR16","first-page":"81","volume":"70","author":"J Gadzik","year":"2006","unstructured":"Gadzik J (2006) \u201cHow much should I weigh?\u201d\u2013Quetelet\u2019s equation, upper weight limits, and BMI prime. Conn Med 70(2):81\u201388","journal-title":"Conn Med"},{"issue":"17","key":"7315_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"Simplified Calculation of Body-Surface Area","year":"1987","unstructured":"Simplified Calculation of Body-Surface Area (1987) N Engl J Med 317(17):1098\u20131098. https:\/\/doi.org\/10.1056\/NEJM198710223171717","journal-title":"N Engl J Med"},{"key":"7315_CR18","doi-asserted-by":"publisher","unstructured":"Chung H, Cobzas D, Birdsell L, Lieffers J, Baracos V (2009) Automated segmentation of muscle and adipose tissue on CT images for human body composition analysis. In: Miga MI, Wong KH (eds) 72610K. https:\/\/doi.org\/10.1117\/12.812412","DOI":"10.1117\/12.812412"},{"issue":"2","key":"7315_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1109\/TMI.2015.2479252","volume":"35","author":"K Popuri","year":"2016","unstructured":"Popuri K, Cobzas D, Esfandiari N, Baracos V, J\u00e4gersand M (2016) Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. IEEE Trans Med Imaging 35(2):512\u2013520. https:\/\/doi.org\/10.1109\/TMI.2015.2479252","journal-title":"IEEE Trans Med Imaging"},{"issue":"8","key":"7315_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1177\/0148607114550189","volume":"38","author":"CMM Prado","year":"2014","unstructured":"Prado CMM, Heymsfield SB (2014) Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr 38(8):940\u2013953. https:\/\/doi.org\/10.1177\/0148607114550189","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"7315_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MCC.0000000000000511","volume":"24","author":"WGPM Looijaard","year":"2018","unstructured":"Looijaard WGPM, Molinger J, Weijs PJM (2018) Measuring and monitoring lean body mass in critical illness. Curr Opin Crit Care 24(4):241\u2013247. https:\/\/doi.org\/10.1097\/MCC.0000000000000511","journal-title":"Curr Opin Crit Care"},{"key":"7315_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nut.2018.06.003","volume":"57","author":"KE Rollins","year":"2019","unstructured":"Rollins KE, Awwad A, Macdonald IA, Lobo DN (2019) A comparison of two different software packages for analysis of body composition using computed tomography images. Nutr Burbank Los Angel Cty Calif 57:92\u201396. https:\/\/doi.org\/10.1016\/j.nut.2018.06.003","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"7315_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"issue":"6","key":"7315_CR24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00520-014-2534-3","volume":"23","author":"M Kimura","year":"2015","unstructured":"Kimura M, Naito T, Kenmotsu H et al (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23(6):1699\u20131708. https:\/\/doi.org\/10.1007\/s00520-014-2534-3","journal-title":"Support Care Cancer"},{"issue":"12","key":"7315_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, MacDonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539\u20131547. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722","journal-title":"J Clin Oncol"},{"issue":"8","key":"7315_CR26","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CMM Prado","year":"2009","unstructured":"Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920\u20132926. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7315_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5):997\u20131006. https:\/\/doi.org\/10.1139\/H08-075","journal-title":"Appl Physiol Nutr Metab"},{"issue":"3","key":"7315_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/apha.12224","volume":"210","author":"J Aubrey","year":"2014","unstructured":"Aubrey J, Esfandiari N, Baracos VE et al (2014) Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 210(3):489\u2013497. https:\/\/doi.org\/10.1111\/apha.12224","journal-title":"Acta Physiol"},{"key":"7315_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"issue":"5","key":"7315_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00330-015-3963-1","volume":"26","author":"D Tamandl","year":"2016","unstructured":"Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A (2016) Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol 26(5):1359\u20131367. https:\/\/doi.org\/10.1007\/s00330-015-3963-1","journal-title":"Eur Radiol"},{"issue":"12","key":"7315_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MAE et al (2016) Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 34(12):1339\u20131344. https:\/\/doi.org\/10.1200\/JCO.2015.63.6043","journal-title":"J Clin Oncol"},{"issue":"3","key":"7315_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/tbj.12952","volume":"24","author":"MS Weinberg","year":"2018","unstructured":"Weinberg MS, Shachar SS, Muss HB et al (2018) Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J 24(3):278\u2013284. https:\/\/doi.org\/10.1111\/tbj.12952","journal-title":"Breast J"},{"issue":"1","key":"7315_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41523-024-00613-x","volume":"10","author":"EJ Gallagher","year":"2024","unstructured":"Gallagher EJ, Moore H, Lacouture ME et al (2024) Managing hyperglycemia and rash associated with Alpelisib: expert consensus recommendations using the Delphi technique. Npj Breast Cancer 10(1):12. https:\/\/doi.org\/10.1038\/s41523-024-00613-x","journal-title":"Npj Breast Cancer"},{"issue":"10","key":"7315_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139749","volume":"10","author":"Y Choi","year":"2015","unstructured":"Choi Y, Oh DY, Kim TY et al (2015) Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS ONE 10(10):e0139749. https:\/\/doi.org\/10.1371\/journal.pone.0139749","journal-title":"PLoS ONE"},{"issue":"4","key":"7315_CR35","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4143\/crt.2015.250","volume":"48","author":"I Park","year":"2016","unstructured":"Park I, Choi SJ, Kim YS et al (2016) Prognostic factors for risk stratification of patients with recurrent or metastatic pancreatic adenocarcinoma who were treated with gemcitabine-based chemotherapy. Cancer Res Treat 48(4):1264\u20131273. https:\/\/doi.org\/10.4143\/crt.2015.250","journal-title":"Cancer Res Treat"},{"issue":"1","key":"7315_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12885-020-07753-w","volume":"21","author":"IH Kim","year":"2021","unstructured":"Kim IH, Choi MH, Lee IS, Hong TH, Lee MAh (2021) Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. BMC Cancer 21(1):77. https:\/\/doi.org\/10.1186\/s12885-020-07753-w","journal-title":"BMC Cancer"},{"issue":"3","key":"7315_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/MCO.0b013e328337d826","volume":"13","author":"I Miljkovic","year":"2010","unstructured":"Miljkovic I, Zmuda JM (2010) Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care 13(3):260\u2013264. https:\/\/doi.org\/10.1097\/MCO.0b013e328337d826","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"7315_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/ijms11041509","volume":"11","author":"SJ Meng","year":"2010","unstructured":"Meng SJ, Yu LJ (2010) Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci 11(4):1509\u20131526. https:\/\/doi.org\/10.3390\/ijms11041509","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7315_CR39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1139\/H07-085","volume":"32","author":"CS Carter","year":"2007","unstructured":"Carter CS, Hofer T, Seo AY, Leeuwenburgh C (2007) Molecular mechanisms of life- and health-span extension: role of calorie restriction and exercise intervention. Appl Physiol Nutr Metab 32(5):954\u2013966. https:\/\/doi.org\/10.1139\/H07-085","journal-title":"Appl Physiol Nutr Metab"},{"key":"7315_CR40","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2147\/DMSO.S410834","volume":"16","author":"H Chen","year":"2023","unstructured":"Chen H, Huang X, Dong M, Wen S, Zhou L, Yuan X (2023) The association between sarcopenia and diabetes: from pathophysiology mechanism to therapeutic strategy. Diabetes Metab Syndr Obes Targets Ther 16:1541\u20131554. https:\/\/doi.org\/10.2147\/DMSO.S410834","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"3","key":"7315_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcsm.12043","volume":"6","author":"TS Bowen","year":"2015","unstructured":"Bowen TS, Schuler G, Adams V (2015) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 6(3):197\u2013207. https:\/\/doi.org\/10.1002\/jcsm.12043","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"7315_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","volume":"183","author":"DG Wang","year":"2020","unstructured":"Wang DG, Barrios DM, Blinder VS et al (2020) Dermatologic adverse events related to the PI3K\u03b1 inhibitor Alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat 183(1):227\u2013237. https:\/\/doi.org\/10.1007\/s10549-020-05726-y","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7315_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jgo.2022.08.007","volume":"13","author":"SS Shachar","year":"2022","unstructured":"Shachar SS, Bar-Sela G, Peer A et al (2022) The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: an Israeli prospective study. J Geriatr Oncol 13(8):1203\u20131207. https:\/\/doi.org\/10.1016\/j.jgo.2022.08.007","journal-title":"J Geriatr Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07315-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:57:06Z","timestamp":1718668626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07315-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7315"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07315-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3865840\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,7]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}